Perakizumab

Perakizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	IL17A
Clinical data
ATC code	none;
Identifiers
CAS Number	1331830-76-2 ;
ChemSpider	none;
UNII	867X5909JO;
Chemical and physical data
Formula	C6454H9964N1718O2030S44
Molar mass	145515.34 g·mol−1

Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis.^[1] It binds to IL17A and acts as an immunomodulator.^[2]

This drug was developed by Genentech/Roche.

References

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Perakizumab, American Medical Association.
^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Perakizumab, American Medical Association.

[2] World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).

[1]

[2]